US Patent

US8440631 — Compositions for drug administration

Method of Use · Assigned to Aegis Therapeutics LLC · Expires 2026-05-09 · 0y expired

Vulnerability score 65/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects compositions that combine an alkyl glycoside with a therapeutic agent, such as a 5-HT receptor agonist, to increase bioavailability and provide migraine pain relief.

USPTO Abstract

The present invention provides compositions and methods and for increasing the bioavailability of therapeutic agents in a subject, as well as compositions and methods for providing migraine pain relief. The compositions include at least one alkyl glycoside and at least one therapeutic agent, such as a 5-HT receptor agonist, wherein the alkylglycoside has an alkyl chain length from about 10 to about 16 carbon atoms.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-1719 Imitrex

Patent Metadata

Patent number
US8440631
Jurisdiction
US
Classification
Method of Use
Expires
2026-05-09
Drug substance claim
No
Drug product claim
Yes
Assignee
Aegis Therapeutics LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.